SERAPHIN haemodynamic substudy: the effect of the dual endothelin receptor antagonist macitentan on haemodynamic parameters and NT-proBNP levels and their association with disease progression in patients with pulmonary arterial hypertension
暂无分享,去创建一个
A. Torbicki | H. Ghofrani | G. Simonneau | O. Sitbon | L. Rubin | R. Souza | T. Pulido | M. Delcroix | N. Galiè | S. Mehta | R. Channick | P. Jansa | F. Le Brun | B. Sastry | L. Perchenet | R. Souza | Franck-Olivier Le Brun
[1] Simon Gibbs,et al. 2015 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. , 2016, Revista espanola de cardiologia.
[2] O. Sitbon,et al. Treatment goals of pulmonary hypertension. , 2013, Journal of the American College of Cardiology.
[3] W. Seeger,et al. Short-Term Improvement in Pulmonary Hemodynamics is Strongly Predictive of Long-Term Survival in Patients with Pulmonary Arterial Hypertension , 2013, Pulmonary circulation.
[4] Z. Jing,et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. , 2013, The New England journal of medicine.
[5] A. Peacock,et al. Predicting survival in pulmonary arterial hypertension in the UK , 2012, European Respiratory Journal.
[6] J. Barberà,et al. Survival in pulmonary hypertension in Spain: insights from the Spanish registry , 2012, European Respiratory Journal.
[7] T. Welte,et al. The prognostic impact of follow-up assessments in patients with idiopathic pulmonary arterial hypertension , 2011, European Respiratory Journal.
[8] Christopher S Coffey,et al. Predicting Survival in Pulmonary Arterial Hypertension: Insights From the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL) , 2010, Circulation.
[9] M. Humbert,et al. Survival in Patients With Idiopathic, Familial, and Anorexigen-Associated Pulmonary Arterial Hypertension in the Modern Management Era , 2010, Circulation.
[10] Sanjiv J. Shah,et al. Survival in pulmonary arterial hypertension: a reappraisal of the NIH risk stratification equation , 2009, European Respiratory Journal.
[11] D. Ivy,et al. Brain natriuretic peptide levels in managing pediatric patients with pulmonary arterial hypertension. , 2009, Chest.
[12] J. Marcus,et al. NT-proBNP reflects right ventricular structure and function in pulmonary hypertension , 2006, European Respiratory Journal.
[13] A. Torbicki,et al. Serum N-terminal brain natriuretic peptide as a prognostic parameter in patients with pulmonary hypertension. , 2006, Chest.
[14] K. Chin,et al. The right ventricle in pulmonary hypertension , 2005, Coronary artery disease.
[15] T. Mueller,et al. Comparison of the Biomedica NT-proBNP enzyme immunoassay and the Roche NT-proBNP chemiluminescence immunoassay: implications for the prediction of symptomatic and asymptomatic structural heart disease. , 2003, Clinical chemistry.
[16] Gilles Garcia,et al. Long-term intravenous epoprostenol infusion in primary pulmonary hypertension: prognostic factors and survival. , 2002, Journal of the American College of Cardiology.
[17] K. Kangawa,et al. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. , 2000, Circulation.
[18] Keith McNeil,et al. International guidelines for the selection of lung transplant candidates. The American Society for Transplant Physicians (ASTP)/American Thoracic Society(ATS)/European Respiratory Society(ERS)/International Society for Heart and Lung Transplantation(ISHLT). , 1998, American journal of respiratory and critical care medicine.